APA (7th ed.) Citation

Antonini, A., Benesh, J., Kukreja, P., Ijacu, H., Bergmann, L., Boyd, J. T., . . . Robieson, W. Z. (2020). Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa. Parkinson's disease, 2020(2020), 1-11. https://doi.org/10.1155/2020/9716317

Chicago Style (17th ed.) Citation

Antonini, Angelo, Janet Benesh, Pavnit Kukreja, Horia Ijacu, Lars Bergmann, James T. Boyd, Werner Poewe, Cindy Zadikoff, and Weining Z. Robieson. "Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa." Parkinson's Disease 2020, no. 2020 (2020): 1-11. https://doi.org/10.1155/2020/9716317.

MLA (9th ed.) Citation

Antonini, Angelo, et al. "Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa." Parkinson's Disease, vol. 2020, no. 2020, 2020, pp. 1-11, https://doi.org/10.1155/2020/9716317.